secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0001193125-23-005171
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports ~$560M cash, 2023 pipeline goals including KT-474 Phase 2 start with Sanofi
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and investments of ~$560M as of Dec 31, 2022, runway into H2 2025.
- KT-474 (IRAK4 degrader) Phase 2 trials in HS and AD to initiate in 2023 in collaboration with Sanofi.
- KT-333 (STAT3) Phase 1 dose escalation ongoing; 66% mean STAT3 degradation in PBMC at first dose level.
- KT-413 (IRAKIMiD) Phase 1 completed two dose levels; dose-dependent degradation of IRAK4, Ikaros, Aiolos; no DLTs.
- KT-253 (MDM2) IND cleared; Phase 1a to start Q1 2023 in solid tumors and hematological malignancies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312523005171/0001193125-23-005171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312523005171/d447672d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-005171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer